Higher Efficacy, But Also More Toxicity of Axicabtagene Ciloleucel Compared to Tisagenlecleucel in Relapsed/Refractory DLBCL
Findings from an individual patient data based matched comparison of efficacy and safety between two commercial CAR T cell products